Scorecard™
Volpara Enterprise DDP™ is now Volpara Scorecard™. Give your breast care team the insights they need to find cancer earlier. Improve clinical decision-making with key breast density and risk insights in one view.
Request a demo
New FDA National Density Reporting Standard
The Food & Drug Administration has updated the Mammography Quality Standards Act (MQSA) to make patient breast density notification a federal requirement.
16.5 m+
Women across 40 countries have had their breast composition assessed by Volpara TruDensity
The only
Volumetric breast density assessment validated for use with Tyrer-Cuzick 8
Decision Support
Triage women for additional breast screening
Science-based data and alerts when patients meet high-risk thresholds for additional detection or preventative care.

Risk Insight 1
Automatic breast composition assessment
Volumetric density measurements validated for Tyrer-Cuzick 8, offering objective, precise, and consistent breast cancer risk assessment.

Risk Insight 2
Lifetime breast cancer risk calculator
Integrated Tyrer-Cuzick 8 risk modeling calculates lifetime risk of developing breast cancer.
*requires additional software purchase

Risk Insight 3
Suspicious findings
AI and machine learning categorize mammograms by likelihood of cancer.
*requires additional software purchase

Product pack info
Detailed product information and data sheet.
Interested? Request a demo or consultation.
Explore
You might be interested in...

FDA national breast density notification requirement
Blog

30 Mar 2023
The Federal Breast Density Inform Rule: Huge Leap Forward, But More To Do
News

10 Mar 2023
FDA Breast Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement